Renal cell carcinoma: updated ESMO guidelines

  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Society for Medical Oncology (ESMO) has published clinical practice guidelines for the diagnosis, treatment and follow-up of renal cell carcinoma (RCC). Key recommendations include:

Laboratory tests 

  • serum creatinine 
  • haemoglobin 
  • leukocyte and platelet counts 
  • lymphocyte:neutrophil ratio 
  • lactate dehydrogenase 
  • C-reactive protein
  • serum corrected calcium

Local/locoregional disease

  • Partial nephrectomy (PN) for organ confined T1 tumours
  • Radiofrequency-, microwave- or cryo-ablation for cortical tumours ≤3 cm.
  • Laparoscopic RN for T2 tumours >7 cm.
  • Open/laparoscopic RN for T3 and T4 tumours.

Advanced/metastatic disease

  • Cytoreductive nephrectomy (CN) for good performance status, except intermediate-/poor-risk asymptomatic primary tumours.
  • Radiotherapy (RT) for unresectable local or recurrent disease.
  • Corticosteroids for temporary relief of cerebral symptoms of brain metastasis. Whole-brain radiotherapy (WBRT) 20-30 Gy in 4-10 fractions for effective symptom control.
  • Stereotactic radiosurgery (SRS)±WBRT for good-prognosis metastatic renal cell carcinoma with single unresectable brain metastasis.
  • First-line systemic treatment for good-/intermediate-risk: VEGF-targeted agents and tyrosine kinase inhibitors (TKIs).
  • Tivozanib for good-risk patients.
  • Nivolumab+ipilimumab for intermediate/poor-risk patients. Cabozantinib now EMA approved.
  • Second-line treatment: nivolumab, cabozantinib or tivozanib after TKI. Lenvatinib+everolimus after nivolumab+ipilimumab. If none of these drugs is available, either everolimus or axitinib can be used.
  • Nivolumab or cabozantinib after two TKIs.